seperator

About Ethris

seperator

Ethris has created a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA (mRNA) and lipidoid nanoparticle (LNP) technology platforms to discover, design and develop innovative therapies and vaccines. As an mRNA pioneer for more than a decade, our technologies enable the delivery of highly potent mRNA-based drug products directly to the upper and lower respiratory tract and via intra-muscular injection. Ethris’ differentiated platforms produce drug candidates with superior thermostability, resistance to mechanical manipulation and are nebulizable at high throughput, without change in biophysical properties or potency. We are developing our first-in-class, virus-agnostic, anti-viral treatment for COVID-19 and influenza while advancing our pipeline of immunomodulation and mRNA-based protein replacement therapies and vaccines with the ultimate goal of improving patients’ lives.

 
READ MORE ABOUT OUR COMPANY

seperator

About Ethris

seperator

Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, we are a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. We are approaching in vivo proof of concept for generating therapeutic antibodies against COVID-19 in the lung while advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients’ lives.

READ MORE

Learn more about our pipeline.

GO TO PIPELINE